paid access

Vol 23, No 2 (2017)
Guidelines
Published online: 2017-05-26
Get Citation

Żylna choroba zakrzepowo-zatorowa — wytyczne profilaktyki, diagnostyki i terapii Konsensus Polski 2017

Witold Tomkowski, Paweł Kuca, Tomasz Urbanek, Dariusz Chmielewski, Zbigniew Krasiński, Piotr Pruszczyk, Jerzy Windyga, Grzegorz Oszkinis, Arkadiusz Jawień, Janusz Burakowski, Małgorzata Dybowska, Jan Kęsik, Tomasz Zubilewicz
Acta Angiologica 2017;23(2):73-113.

paid access

Vol 23, No 2 (2017)
Guidelines
Published online: 2017-05-26

Abstract

Polish Consensus Statement 2017 (PCS 2017) comprises updated recommendations on prophylaxis, diagnostic approach and treatment of venous thromboembolism (VTE). For VTE and no cancer, as long-term anticoagulant therapy, the authors of PCS 2017 recommend apixaban, edoxaban, rivaroxaban and dabigatran over vitamin K antagonists (VKA). For VTE and cancer, the authors of PCS 2017 recommend low molecular weight heparins (LMWH) over VKA, apixaban, edoxaban, rivaroxaban and dabigatran. For extended prophylaxis of deep venous thrombosis (DVT), PCS 2017 recommends apixaban, edoxaban, rivaroxaban, dabigatran, VKA and sulodexide. For extended prophylaxis of pulmonary embolism (PE) PCS 2017 recommends apixaban, edoxaban, rivaroxaban, dabigatran and VKA. In extended prophylaxis, for patients with idiopathic DVT and high risk of bleeding complications, the authors of PCS 2017 recommend DO NOT stop anticoagulation and use of sulodexide. In extended prophylaxis, for patients with idiopathic PE and high risk of bleeding, the authors of PCS 2017 recommend DO NOT stop anticoagulation and suggests treatment with apixaban, edoxaban, rivaroxaban and dabigatran in reduced doses — adjusted to the risk of bleeding. For VTE treated with anticoagulants, PCS 2017 recommends against insertion of vena cava filters. For patients with DVT, PCS 2017 suggests USING compression stockings routinely to prevent post thrombotic syndrome. For sub-segmental PE and no proximal DVT, PCS suggests clinical surveillance over anticoagulation with a low risk of recurrent VTE, and anticoagulation over clinical surveillance with a high risk. Polish Consensus Statement 2017 suggests thrombolytic therapy for PE with hypotension and systemic therapy over catheter directed thrombolysis. For recurrent VTE on a non-LMWH anticoagulant, PCS suggests LMWH, and for recurrent DVT and/or PE on LMWH PCS 2017 suggests increasing the LMWH dose.

Abstract

Polish Consensus Statement 2017 (PCS 2017) comprises updated recommendations on prophylaxis, diagnostic approach and treatment of venous thromboembolism (VTE). For VTE and no cancer, as long-term anticoagulant therapy, the authors of PCS 2017 recommend apixaban, edoxaban, rivaroxaban and dabigatran over vitamin K antagonists (VKA). For VTE and cancer, the authors of PCS 2017 recommend low molecular weight heparins (LMWH) over VKA, apixaban, edoxaban, rivaroxaban and dabigatran. For extended prophylaxis of deep venous thrombosis (DVT), PCS 2017 recommends apixaban, edoxaban, rivaroxaban, dabigatran, VKA and sulodexide. For extended prophylaxis of pulmonary embolism (PE) PCS 2017 recommends apixaban, edoxaban, rivaroxaban, dabigatran and VKA. In extended prophylaxis, for patients with idiopathic DVT and high risk of bleeding complications, the authors of PCS 2017 recommend DO NOT stop anticoagulation and use of sulodexide. In extended prophylaxis, for patients with idiopathic PE and high risk of bleeding, the authors of PCS 2017 recommend DO NOT stop anticoagulation and suggests treatment with apixaban, edoxaban, rivaroxaban and dabigatran in reduced doses — adjusted to the risk of bleeding. For VTE treated with anticoagulants, PCS 2017 recommends against insertion of vena cava filters. For patients with DVT, PCS 2017 suggests USING compression stockings routinely to prevent post thrombotic syndrome. For sub-segmental PE and no proximal DVT, PCS suggests clinical surveillance over anticoagulation with a low risk of recurrent VTE, and anticoagulation over clinical surveillance with a high risk. Polish Consensus Statement 2017 suggests thrombolytic therapy for PE with hypotension and systemic therapy over catheter directed thrombolysis. For recurrent VTE on a non-LMWH anticoagulant, PCS suggests LMWH, and for recurrent DVT and/or PE on LMWH PCS 2017 suggests increasing the LMWH dose.

Get Citation

Keywords

brak

About this article
Title

Żylna choroba zakrzepowo-zatorowa — wytyczne profilaktyki, diagnostyki i terapii Konsensus Polski 2017

Journal

Acta Angiologica

Issue

Vol 23, No 2 (2017)

Pages

73-113

Published online

2017-05-26

Bibliographic record

Acta Angiologica 2017;23(2):73-113.

Keywords

brak

Authors

Witold Tomkowski
Paweł Kuca
Tomasz Urbanek
Dariusz Chmielewski
Zbigniew Krasiński
Piotr Pruszczyk
Jerzy Windyga
Grzegorz Oszkinis
Arkadiusz Jawień
Janusz Burakowski
Małgorzata Dybowska
Jan Kęsik
Tomasz Zubilewicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl